Toll-Like Receptor 7 Is Required for Lacrimal Gland Autoimmunity and Type 1 Diabetes Development in Male Nonobese Diabetic Mice. by Debreceni, Ivy L et al.
The Jackson Laboratory 
The Mouseion at the JAXlibrary 
Faculty Research 2020 Faculty Research 
12-13-2020 
Toll-Like Receptor 7 Is Required for Lacrimal Gland Autoimmunity 
and Type 1 Diabetes Development in Male Nonobese Diabetic 
Mice. 
Ivy L Debreceni 
Michael S Chimenti 
David V. Serreze 
Aron M Geurts 
Yi-Guang Chen 
See next page for additional authors 
Follow this and additional works at: https://mouseion.jax.org/stfb2020 
 Part of the Life Sciences Commons, and the Medicine and Health Sciences Commons 
Authors 
Ivy L Debreceni, Michael S Chimenti, David V. Serreze, Aron M Geurts, Yi-Guang Chen, and Scott M 
Lieberman 
 International Journal of 
Molecular Sciences
Article
Toll-Like Receptor 7 Is Required for Lacrimal Gland
Autoimmunity and Type 1 Diabetes Development in
Male Nonobese Diabetic Mice
Ivy L. Debreceni 1,2 , Michael S. Chimenti 3, David V. Serreze 4 , Aron M. Geurts 5,
Yi-Guang Chen 6,7 and Scott M. Lieberman 1,2,*
1 Stead Family Department of Pediatrics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242,
USA; ivy-gandy@uiowa.edu
2 Immunology Graduate Program, University of Iowa, Iowa City, IA 52242, USA
3 Iowa Institute of Human Genetics, Carver College of Medicine, University of Iowa, Iowa City, IA 52242,
USA; michael-chimenti@uiowa.edu
4 The Jackson Laboratory, Bar Harbor, ME 04609, USA; dave.serreze@jax.org
5 Department of Physiology and Cardiovascular Center, Medical College of Wisconsin, Milwaukee, WI 53226,
USA; ageurts@mcw.edu
6 Department of Pediatrics, Department of Microbiology and Immunology, Medical College of Wisconsin,
Milwaukee, WI 53226, USA; yichen@mcw.edu
7 Max McGee National Research Center for Juvenile Diabetes, Medical College of Wisconsin, Milwaukee,
WI 53226, USA
* Correspondence: scott-lieberman@uiowa.edu; Tel.: +1-319-467-5111
Received: 11 November 2020; Accepted: 9 December 2020; Published: 13 December 2020 
Abstract: Sjögren syndrome (SS) is an immunologically complex, chronic autoimmune disease targeting
lacrimal and salivary glands. Nonobese diabetic (NOD) mice spontaneously develop inflammation
of lacrimal and salivary glands with histopathological features similar to SS in humans including
focal lymphocytic infiltrates in the affected glands. The innate immune signals driving lymphocytic
infiltration of these glands are not well-defined. Here we evaluate the role of Toll-like receptor (TLR) 7
in the development of SS-like manifestations in NOD mice. We created a Tlr7 knockout NOD mouse
strain and performed histological and gene expression studies to characterize the effects of TLR7 on
autoimmunity development. TLR7 was required for male-specific lacrimal gland inflammation but
not for female-specific salivary gland inflammation. Moreover, TLR7 was required for type 1 diabetes
development in male but not female NOD mice. RNA sequencing demonstrated that TLR7 was
associated with a type I interferon (IFN) response and a type I IFN-independent B cell response in the
lacrimal glands. Together these studies identify a previously unappreciated pathogenic role for TLR7
in lacrimal gland autoimmunity and T1D development in male NOD mice adding to the growing
body of evidence supporting sex differences in mechanisms of autoimmune disease in NOD mice.
Keywords: Sjögren syndrome; type 1 diabetes; Toll-like receptor 7; lacrimal gland; salivary gland
1. Introduction
Sjögren syndrome (SS) is a chronic autoimmune disease that primarily targets lacrimal and salivary
glands leading to progressive exocrine gland dysfunction and debilitating ocular and oral dryness [1].
The ensuing poor ocular and oral health may lead to defects in vision and difficulty with normal oral
function such as talking and swallowing. Beyond these glandular manifestations, many individuals
with SS develop autoimmunity affecting other organs, chronic musculoskeletal pain, and profound
fatigue. The chronic immune stimulation is believed to contribute to the markedly increased risk of
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developing lymphoma. Current treatments largely aim to replace or augment tears and saliva but
fail to adequately halt or reverse the chronic inflammation to prevent damage or progressive exocrine
gland dysfunction. The lack of well-established therapeutics to modulate the immune response may
relate to the gap in understanding of the early immunopathogenic mechanisms driving the exocrine
gland inflammation.
Toll-like receptors (TLRs) are pattern recognition receptors that recognize a wide range of pathogen
and damage associated molecules [2]. TLR signals in innate and adaptive immune cells play early roles
in immune responses and have been linked to infections, cancer, and autoimmunity [3,4]. Studies
of human salivary gland tissue, peripheral blood mononuclear cells (PBMCs), and mouse models of
SS have identified pathogenic roles for several cell surface and intracellular TLRs in salivary gland
autoimmunity [5]. TLRs are expressed at the ocular surface [6], but evidence for the role of TLRs in
lacrimal gland autoimmunity is limited. Administration of a TLR3 agonist resulted in lacrimal gland
inflammation in a non-autoimmune-prone mouse strain (C57BL/6) [7]. In an autoimmune-prone strain
of mouse that spontaneously develops SS-like manifestations (NOD. B10Sn-H2b/J) lacrimal gland
inflammation decreased when Myd88, which encodes a key adaptor in the signaling pathways of
multiple TLRs, was disrupted [8] suggesting a pathogenic role for MyD88-dependent TLRs. TLR7 is
MyD88-dependent, and a role for TLR7 was suggested by development of spontaneous lacrimal gland
inflammation in autoimmune-prone mice (BXSB/MpJ-Yaa) in which males have increased expression
of TLR7 [9].
TLR7, an endosomal TLR, has been implicated in multiple autoimmune diseases including SS and
type 1 diabetes (T1D) [10–13]. TLR7 recognizes uridine-rich ssRNA and guanosine [14] and is expressed
in monocytes, macrophages, dendritic cells, and B cells. Signaling through TLR7 is MyD88-dependent
and uses NF-κB and interferon (IFN) regulatory factor pathways to drive expression of type I IFN and
other inflammatory cytokines. In SS, TLR7 expression was increased in PBMCs, and this increased
expression positively correlated with IFN signatures in SS patients [15,16]. TLR7 has been detected
in labial minor salivary glands of SS patients with expression noted in ductal cells and infiltrating
immune cells [16,17]. A role for TLR7 has not been evaluated in nonobese diabetic (NOD) mice, which
spontaneously develop SS-like manifestations and are a well-established model for the study of SS-like
lacrimal and salivary gland autoimmunity [18].
The purpose of this study was to define the role of TLR7 in the spontaneous development of
SS-like autoimmunity in NOD mice. We developed gene-edited NOD mice lacking Tlr7 expression
and found that male mice lacking TLR7 were protected from the spontaneous development of lacrimal
gland inflammation, whereas females were not protected from spontaneous salivary gland inflammation.
NOD mice are also a model of T1D given the spontaneous development of T1D in both sexes. In the
absence of TLR7, male NOD mice were protected from T1D development, but females were not protected.
Through RNA sequencing studies, we identified genes and pathways up-regulated in lacrimal glands of
wild-type NOD mice compared to TLR7-deficient NOD mice and compared this gene set to a set of genes
up-regulated in lacrimal gland disease in a type I IFN-dependent manner. Together, our findings suggest
TLR7 plays a key pathogenic role in the development of lacrimal gland autoimmunity associated with a
type I IFN response and with B cell responses in situ in a type I IFN-independent manner.
2. Results
2.1. Development of Tlr7 Knockout NOD Mice
To evaluate the role of TLR7 in the development of autoimmunity in NOD mice, we developed
Tlr7 knockout (KO) NOD mice through CRISPR/Cas9-mediated gene editing directly in NOD mouse
embryos resulting in a 2 base-pair deletion in Tlr7 (Figure 1A). Tlr7 KO genotype was confirmed by
gene sequencing, and lack of TLR7 protein in both male and female splenocytes was confirmed by
intracellular flow cytometry (Figure 1B–D).
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Figure 1. Generation and validation of Tlr7 KO NOD mice. (A) Schematic of the Tlr7 gene including 
the relevant sequence in wild-type NOD mice (NOD) and the 2 base-pair deletion mediated by 
CRISPR/Cas9 targeting of Tlr7 in NOD embryos resulting in the Tlr7 KO (NOD. Tlr7−/−) strain used in 
our studies. Boxes represent exons with the filled portions representing the coding regions. (B) 
Representative flow cytometry histograms demonstrating lack of TLR7 protein in splenocytes of wild-
type (WT) and Tlr7 KO (KO) NOD females (top) and males (bottom) as indicated. Splenocytes were 
permeabilized for intracellular staining with a TLR7-specific (solid black lines) or an isotype control 
(filled gray histograms) antibody (x-axis). Plots are gated on CD11c+B220+ singlets and are normalized 
to mode (y-axis). (C,D) Cumulative quantitation (geometric mean fluorescence intensity, gMFI) of 
TLR7 expression in cells represented in (B) from female (C) or male (D) WT or Tlr7 KO NOD mice. 
Symbols represent individual mice (5–8 per group), lines are means. p-value by unpaired t-test with 
Welch’s correction for unequal variance where necessary. 
2.2. TLR7-Deficient NOD Mice Are Protected from Autoimmunity in a Sex-Specific Manner 
NOD mice spontaneously develop autoimmunity targeting lacrimal and salivary glands (SS-like 
manifestations) and insulin-producing β cells in the endocrine pancreas (T1D manifestations). The 
SS-like manifestations occur in a sex-specific manner with males spontaneously developing lacrimal 
gland inflammation and females spontaneously developing salivary gland inflammation, while T1D 
manifestations occur in both sexes [19–22]. To determine the role of TLR7 in the SS-like autoimmune 
manifestations, we quantitated inflammation in lacrimal and salivary glands of 10-week-old WT and 
Tlr7 KO NOD mice by standard focus-scoring. Lacrimal gland inflammation was markedly 
diminished with little to no inflammation detected in the glands from male Tlr7 KO mice compared 
to WT male mice (Figure 2A,B). Neither WT nor Tlr7 KO female mice developed lacrimal gland 
inflammation (Figure 2C,D) in accordance with the known male-specific occurrence of spontaneous 
lacrimal gland autoimmunity in NOD mice [19,23]. In contrast, females developed focal sialadenitis 
to a similar degree regardless of the presence or absence of TLR7 (Figure 2E,F). In accordance with 
the female-specific occurrence of spontaneous salivary gland autoimmunity in NOD mice ([20]), WT 
Figure 1. Generation and validation of Tlr7 KO NOD mice. (A) Schematic of the Tlr7 gene including the
relevant sequence in wild-type NOD mice (NOD) and the 2 base-pair deletion mediated by CRISPR/Cas9
targeting of Tlr7 in NOD embryos resulting in the Tlr7 KO (NOD. Tlr7−/−) strain used in our studies.
Boxes represent exons with the filled portions representing the coding regions. (B) Representative flow
cytometry histograms demonstrating lack of TLR7 protein in splenocytes of wild-type (WT) and Tlr7
KO (KO) NOD females (top) and males (bottom) as indicated. Splenocytes were permeabilized for
intracellular staining with a TLR7-specific (solid black lines) or an isotype control (filled gray histograms)
antibody (x-axis). Plots are gated on CD11c+B220+ singlets and are normalized to mode (y-axis). (C,D)
Cumulative quantitation (geometric mean fluorescence intensity, gMFI) of TLR7 expression in cells
represented in (B) from female (C) or male (D) WT or Tlr7 KO NOD mice. Symbols represent individual
mice (5–8 per group), lines are means. p-value by unpaired t-test with Welch’s correction for unequal
variance where necessary.
2.2. TLR7-Deficient NOD Mice Are Protected from Autoimmunity in a Sex-Specific Manner
NOD mice spontaneously develop autoimmunity targeting lacrimal and salivary glands (SS-like
manifestations) and i sulin-producing β cells in the endocrine pancreas (T1D manifestations).
The SS-like manifestations occur in a sex-specific mann r with males spontaneously developing lacrimal
gland inflammation and females spontaneously developing salivary gland inflammation, while T1D
manifestations occur in both s xes [19–22]. To det rmine the role of TLR7 in the SS-like autoimmune
anifestatio s, we quantitated inflammation in lacrimal and salivary glands of 10-we k-old WT a d
Tlr7 KO NOD mic by standar focus-scoring. Lacrimal glan inflammation was markedly diminished
with little to no inflammation detected in the glands from male Tlr7 KO mice compared to WT male
mice (Figure 2A,B). Neither WT nor Tlr7 KO female mice developed lacrimal gland inflamm tion
(Figure 2C,D) in accordance with th known male-specific occurrence of spontaneous lacrimal gland
autoimmunity in NOD mice [19,23]. In contrast, females develop d focal sialadenitis to a similar d gree
regardless of the presence or absence of TLR7 (Figure 2E,F). In accordance with the female-specific
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occurrence of spontaneous salivary gland autoimmunity in NOD mice ([20]), WT male NOD mice
did not develop salivary gland inflammation (Figure 2G,H). Surprisingly, Tlr7 KO male NOD mice
developed some salivary gland inflammation (Figure 2G,H). T1D developed in most of both female
and male WT NOD mice, but only male Tlr7 KO mice were protected from T1D with 16 of 17 Tlr7 KO
male NOD mice diabetes free at 30 weeks (Figure 2I,J). While Tlr7 is an X-linked gene that may escape
X-linked inactivation [24], this does not explain the lack of protection from autoimmunity in female
Tlr7 KO mice given that the Tlr7 KO NOD mice expressed no detectable TLR7 protein regardless of
sex (Figure 1B–D). These data demonstrate a requirement for TLR7 in the development of lacrimal
gland inflammation and T1D in male NOD mice but not for salivary gland inflammation or T1D in
female NOD mice. Yet, the male-specific protection from autoimmunity was not global as the lack
of TLR7 resulted in an increase in salivary gland inflammation in male mice. Thus, TLR7 may play
more complex disease-promoting and disease-protecting functions depending on the target organ in
male NOD mice, but TLR7 deficiency did not alter autoimmunity in either SS or T1D manifestations in
female NOD mice.
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indicated below each image. Scale bars are 1 mm. (E,G) Quantitation of sialadenitis in 10-week-old 
WT or Tlr7 KO female (E) or male (G) mice. Symbols, lines, scale bars, and p-value as in (A). ns, not 
significant. (F,H) Representative H&E-stained sections of salivary glands from (E or G) as indicated. 
(I,J) T1D incidence of male (I) and female (J) WT and Tlr7 KO mice with indicated p-value by Log-
rank test. ns, not significant. 
2.3. RNA Sequencing of Whole Lacrimal Gland Tissue Implicates Key Immune Genes and Pathways 
Given the broad possible TLR7-associated downstream signals among different immune and 
non-immune cells that may participate in lacrimal gland inflammation, we evaluated whole tissue 
Figure 2. Male Tlr7 KO NOD mice are protected from lacrimal gland autoimmunity and T1D development.
(A,C) Quantitation of lacrimal gland inflammation in 10-week-old WT or Tlr7 KO male (A) or female (C)
mice. Focus score equals number of inflammatory foci (minimum of 50 mononuclear cells per focus) per
4 mm2. Symbols represent individual mice (males: n = 15 WT, n = 6 Tlr7 KO; females: n = 13 WT, n =
9 Tlr7 KO), lines are medians. p-value by Mann-Whitney test. (B,D) Representative hematoxylin and
eosin (H&E) stained sections of lacrimal glands from (A or C) as indicated below each image. Scale bars
are 1 mm. (E,G) Quantitation of sialadenitis in 10-week-old WT or Tlr7 KO female (E) or male (G) mice.
Symbols, lines, scale bars, and p-value as in (A). ns, not significant. (F,H) Representative H&E-stained
sections of salivary glands from (E or G) as indicated. (I,J) T1D incidence of male (I) and female (J) WT
and Tlr7 KO mice with indicated p-value by Log-rank test. ns, not significant.
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2.3. RNA Sequencing of Whole Lacrimal Gland Tissue Implicates Key Immune Genes and Pathways
Given the broad possible TLR7-associated downstream signals among different immune and
non-immune cells that may participate in lacrimal gland inflammation, we evaluated whole tissue
gene expression patterns to identify genes and pathways that were up-regulated in lacrimal glands of
WT compared to Tlr7 KO NOD mice. We performed RNA sequencing on whole tissue RNA samples
from lacrimal glands of WT and Tlr7 KO NOD mice at ~20 weeks of age, a time when lacrimal gland
inflammation was clear in WT but only minimally detected in KO NOD mice (Figure 3A). We identified
3936 significantly differentially expressed (DE) genes including 1398 genes with at least 2-fold-change
between WT and KO. Of these, 1205 genes were up-regulated in WT and 193 were up-regulated in KO
lacrimal glands (Figure 3B, Supplemental Table S1). Among the genes with highest differential expression
up-regulated in WT were immunoglobulin genes, complement C4a, cytokines, chemokines, and other
innate immunity genes (Table 1, Supplemental Table S1). To identify relevant TLR7-dependent pathways
associated with lacrimal gland inflammation, we performed pathway analyses using the iPathwayGuide
platform, which includes over-representation analysis of DE genes and, where applicable, incorporates
the perturbation through impact analysis for pathways that have clear gene-gene interactions and
directionality [25] (Tables 2–4, Supplemental Tables S2–S4). We validated the differential gene expression
for several genes from those mostly highly DE and from the cytokine-cytokine receptor pathway
(Figure 4).
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Figure 3. Identification of DE genes up-regulated in lacrimal glands of WT compared to Tlr7 KO NOD
mice. Lacrimal glands were isolated from 20–22-week-old WT (n = 3) or Tlr7 KO (n = 5) NOD mice. One
gland from each mouse was prepared for histological analyses to quantify inflammation. The other gland
was used for RNA sequencing studies. (A) Quantitation of lacrimal gland inflammation by focus-scoring
as in Figure 1. Symbols represent individual mice, lines are medians. p-value by Mann-Whitney test.
(B) Volcano plot of DE genes in lacrimal glands of NOD mice with genes up-regulated in WT or KO
as indicated above the graph. Dots represent individual genes with blue indicating at least 2-fold
up-regulation in WT and black indicating at least 2-fold up-regulation in KO. Gray genes are up-regulated
with fold-change less than 2. Select genes up-regulated in WT are indicated to the left of their respective
data points (except Ighg2c, which is above the data point).
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Table 1. Top 20 DE genes up-regulated in lacrimal glands of WT mice compared to Tlr7 KO mice 1.
Protein Name Gene Symbol Ensembl ID LogFC p-Value 2
Immunoglobulin heavy constant gamma 2C Ighg2c ENSMUSG00000076612 −7.82263 9.82 × 10−16
Complement 4a C4a ENSMUSG00000015451 −5.34572 8.51 × 10−7
Immunoglobulin heavy variable 9-1 Ighv9-1 ENSMUSG00000096805 −5.33515 8.83 × 10−9
Immunoglobulin heavy constant gamma 2B Ighg2b ENSMUSG00000076613 −5.07854 4.75 × 10−38
Interleukin-21 Il21 ENSMUSG00000027718 −4.57119 0.002267
Glutamate decarboxylase 1 Gad1 ENSMUSG00000070880 −4.54398 5.80 × 10−5
RIKEN cDNA G530011O06 gene G530011O06Rik ENSMUSG00000072844 −3.95434 8.40 × 10−8
histocompatibility 2, O region beta locus H2-Ob ENSMUSG00000041538 −3.94349 0.000705
Asialoglycoprotein receptor 1 Asgr1 ENSMUSG00000020884 −3.90959 1.26 × 10−17
Junctional cadherin complex regulator Jhy ENSMUSG00000032023 −3.86272 0.003172
Receptor-type tyrosine-protein phosphatase V Ptprv ENSMUSG00000097993 −3.81638 0.006741
Sclerostin domain containing 1 Sostdc1 ENSMUSG00000036169 −3.81371 0.000239
Mitogen-activated protein kinase kinase kinase 19 Map3k19 ENSMUSG00000051590 −3.78867 0.001609
B cell activating factor receptor (BAFF-R) Tnfrsf13c ENSMUSG00000068105 −3.77041 0.00071
Alpha-1-antitrypsin 1-1 Serpina1a ENSMUSG00000066366 −3.76237 0.032582
Hepatitis A virus cellular receptor 1 Havcr1 ENSMUSG00000040405 −3.72396 0.003191
C-X-C motif chemokine receptor 5 Cxcr5 ENSMUSG00000047880 −3.63713 0.001409
carbohydrate sulfotransferase 3 Chst3 ENSMUSG00000057337 −3.53362 0.000264
Fc receptor-like 1 Fcrl1 ENSMUSG00000059994 −3.52988 0.000323
Polyunsaturated fatty acid (12S)/(13S)-lipoxygenase, epidermal-type Alox12e ENSMUSG00000018907 −3.51249 1.13 × 10−12
1 DE, differentially expressed; FC, fold-change (KO relative to WT); KO, knockout; WT, wild-type. 2 p-value adjusted for multiple comparisons by Benjamini–Hochberg procedure.
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Table 2. Pathways enriched in WT lacrimal glands 1.
Pathway DE Genes/Total p-Value 2
Cell adhesion molecules 66/101 4.34 × 10−10
Cytokine-cytokine receptor interaction 76/139 3.63 × 10−6
Antigen processing and presentation 39/63 3.63 × 10−6
Phagosome 71/131 1.04 × 10−5
Human T cell leukemia virus 1 infection 93/200 7.06 × 10−5
Natural killer cell mediated cytotoxicity 41/77 0.000132
Complement and coagulation cascades 27/45 0.000173
Leukocyte transendothelial migration 46/88 0.000248
Hematopoietic cell lineage 41/69 0.000349
Viral myocarditis 40/56 0.000494
1 DE, differentially expressed, WT, wild-type. 2 p-value with Bonferroni correction for multiple comparisons.
Table 3. Top DE genes in cell adhesion molecules pathway 1.
Gene Ensembl ID LogFC p-Value 2
H2-Ob ENSMUSG00000041538 −3.94349 0.000705275
Cd22 ENSMUSG00000030577 −3.31601 0.000119483
Glycam1 ENSMUSG00000022491 −3.13053 0.01223442
Pdcd1 ENSMUSG00000026285 −3.08293 2.57387 × 10−6
H2-Oa ENSMUSG00000024334 −3.06688 0.000401944
Sell ENSMUSG00000026581 −2.80719 0.008678722
Cd2 ENSMUSG00000027863 −2.76434 0.010163565
H2-DMb2 ENSMUSG00000037548 −2.76392 0.001751811
H2-Q7 ENSMUSG00000060550 −2.59737 0.018849387
Ctla4 ENSMUSG00000026011 −2.56514 0.010040012
1 DE, differentially expressed; FC, fold-change (KO relative to WT). 2 p-value with Bonferroni correction for
multiple comparisons.
Table 4. Top DE genes in cytokine-cytokine receptor interaction pathway 1.
Gene Ensembl ID LogFC p-Value 2
Il21 ENSMUSG00000027718 −4.57119 0.002267
Tnfrsf13c ENSMUSG00000068105 −3.77041 0.00071
Cxcr5 ENSMUSG00000047880 −3.63713 0.001409
Ccl20 ENSMUSG00000026166 −3.39023 0.000001
Cxcr4 ENSMUSG00000045382 −3.24664 0.000001
Cxcl13 ENSMUSG00000023078 −3.00501 0.000001
Ccr6 ENSMUSG00000040899 −2.91986 7.71 × 10−5
Tnfsf8 ENSMUSG00000028362 −2.73458 0.00033
Ccl19 ENSMUSG00000071005 −2.70432 0.02331
Ltb ENSMUSG00000024399 −2.64806 0.002418
1 DE, differentially expressed; FC, fold-change (KO relative to WT). 2 p-value with Bonferroni correction for
multiple comparisons.
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Figure 4. Validation of immune genes up-regulated in WT compared to Tlr7 KO lacrimal glands. Graphs
depict log-transformed relative expression of indicated genes normalized to housekeeping gene Hexokinase
2 (Hk2) in lacrimal glands of 20–21-week-old male WT (n = 5) or Tlr7 KO (n = 5) NOD mice (x-axis).
Symbols represent individual mice. Solid lines are medians. Broken lines represent y-axis zero-value for
reference given the different y-axis ranges. p-values by Mann-Whitney test. nd, not detected.
2.4. TLR7 Drives Up-regulation of Type I IFN-Dependent and -Independent Genes in Lacrimal Glands
We have previously demonstrated that type I IFN signaling is required for lacrimal gland
inflammation in NOD mice [23]. Given that TLR7 is a known driver of type I IFN, we wondered to what
extent the gene expression profiles above reflected the lack of a type I IFN response in Tlr7 KO mice.
To address this, we compared the set of genes up-regulated in lacrimal glands of WT compared to Tlr7
KO NOD mice (Figure 3B) with a similar set of genes up-regulated in lacrimal glands of WT compared
to type I IFN signaling-deficient (Ifnar1 KO) NOD mice [26]. Of note, these data were generated at the
same time and the WT reference group is the same for both comparisons. We limited our analysis to
those genes significantly DE with at least 2-fold increased expression in WT compared to the relative KO
lacrimal glands. Of the 1205 TLR7-dependent genes up-regulated in lacrimal glands of WT NOD mice,
997 (83%) were also up-regulated in a type I IFN-dependent manner (Figure 5A, Supplemental Table S5).
These genes were enriched for clusters of pathways and processes involved in T cell and adaptive
immune responses (Figure 5B, middle). A smaller set of genes (208) was uniquely up-regulated in
WT lacrimal glands in a TLR7-dependent but IFNAR1-independent manner (Figure 5A, Supplemental
Table S5), and these genes were enriched for B cell responses (Figure 5B, top). Genes up-regulated in
WT lacrimal glands in an IFNAR1-dependent but TLR7-independent manner enriched for clusters of
pathways and processes of innate immune functions (Figure 5B, bottom). Together, these data indicate
that TLR7 largely drives a type I IFN response but that type I IFN drives a separate set of innate immune
genes in a TLR7-independent manner, while TLR7 drives B cell-related processes within the lacrimal
glands in a type I IFN-independent manner.
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(A) Vertical slices graph of DE genes up-regulated at least 2-fold in lacrimal glands of WT compared to
either Tlr7 KO (TLR7-dependent) or Ifnar1 KO (IFNAR1-dependent) NOD mice demonstrating those
genes unique to the TLR7 data set (black), common to both data sets (gray), or unique to the IFNAR1
data set (white). (B) Bar graphs depict the enrichment clusters of processes and pathways (GO, KEGG,
Reactome) based on genes from the three different categories in (A) as indicated. X-axes represent the
negative log of the q-value, calculated using Benjamini–Hochberg procedure, and are on the same scale
as indicated at the bottom.
3. Discussion
TLR7 has been implicated in multiple autoimmune diseases including SS and T1D [10–13]. As an
X-linked gene, TLR7 ay escape X-linked inactivation leading to increased TLR7 levels that have
been associated with increased systemic autoimmunity (such as SS) in individuals with more than
one X chromosome [24,27,28]. Here, we evaluated the role of TLR7 in the spontaneous autoimmune
manifestations in NOD mice by creating Tlr7 KO NOD mice. We found that male NOD mice were
protected from development of lacrimal gland inflammation and T1D development, while female
NOD mice were not protected from developing salivary gland inflammation or T1D. This was not due
to an X-linked phenomenon as TLR7 protein was not detected in either male or female Tlr7 KO mice.
Surprisingly, TLR7-deficiency resulted in development of salivary gland inflammation in some males,
but no females (WT or Tlr7 KO) developed lacrimal gland inflammation. These data suggest different
disease mechanisms in the development of SS and T1D manifestations in male and female NOD mice
with a role for TLR7 in promoting or protecting from disease manifestations in males but not females.
For the SS manifestations, we have previously demonstrated that male-specific lacrimal gland
inflammation required intact type I IFN signaling [23]. In contrast, female salivary gland inflammation
required intact type II IFN signaling as Ifng or Ifngr KO NOD mice failed to develop salivary gland
inflammation [29]. Interestingly, male type II IFN signaling-deficient NOD mice were not protected
from development of lacrimal gland inflammation [29], and female type I IFN signaling-deficient NOD
mice were not protected from developing salivary gland inflammation (our unpublished observation).
Thus, the two sex-dependent SS manifestations in NOD mice are dependent on different IFN signaling
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pathways. Studies in humans have demonstrated that a positive IFN-signature in individuals with
SS may be dominated by type I IFN, type II IFN, or a combination of type I and type II IFN [30].
Together, these findings suggest that spontaneous SS-like disease in NOD mice may represent two
different mechanisms of disease found in humans, with lacrimal gland disease in male NOD mice
representing the type I IFN-dependent disease in humans and salivary gland disease in female NOD
mice representing the type II IFN-dependent disease in humans. This is supported in part by recent
demonstration of similarities in gene expression profiles in lacrimal glands of male NOD mice and
salivary glands of humans, though that study did not specifically limit the human data to type I
IFN-dominant disease [31].
TLR7 signaling is a well-established type I IFN-driving stimulus, which is in accordance with
our findings of the requirement of TLR7 for male-specific lacrimal gland inflammation in NOD mice
but not for female-specific salivary gland disease. In support of this, a large majority (>80%) of genes
up-regulated in lacrimal glands of WT NOD mice in a TLR7-dependent manner overlap with those
genes up-regulated in a type I IFN-signaling-dependent manner. These genes were enriched for
pathways involved in the adaptive immune response. Interestingly, though, the smaller portion of
genes up-regulated in a TLR7- but not IFNAR1-dependent manner enriched for pathways related
to B cell responses suggesting a unique role for TLR7 signaling in B cell responses within lacrimal
glands. In SS, B cells may play pathogenic roles through several mechanisms including production of
autoantibodies, presentation of autoantigens to T cells, and production of inflammatory cytokines [32].
In B cell-deficient NOD mice, the initiation of lacrimal and salivary gland inflammation was not
prevented [33]. However, in WT NOD mice, B cells are present within gland infiltrates and accumulate
in the lacrimal glands over time [31,34]. Together with our data here, these studies suggest that B cells
are not required for initiation of exocrine gland inflammation but may contribute to the continued
inflammation within the glands in a TLR7-dependent manner. In support of a pathogenic role for
TLR7 in lacrimal gland inflammation, male BXSB/MpJ-Yaa mice develop spontaneous lacrimal gland
inflammation [9]. These mice express higher levels of TLR7 due to translocation of X chromosome
genes including Tlr7 to the Y chromosome resulting in increased TLR7 protein expression [35]. Notably,
the lacrimal gland infiltrates in these mice were dominated by B cells [9]. In B cells from humans with
SS, TLR7 up-regulation has also been reported [16,36]. TLR7 is expressed by many cells beyond B cells,
and additional studies are necessary to determine if the pathogenic role of TLR7 in driving lacrimal
gland inflammation in NOD mice is B cell-intrinsic and/or dependent on other TLR7-expressing cells.
While the different IFN-dependencies in the sex-specific SS manifestations in NOD mice may
explain the male-specific protection from lacrimal gland disease in Tlr7 KO mice, this does not explain
the sex differences in T1D protection. Studies of IFN signaling-deficient NOD mice suggested a more
complex role for type I and II IFN signaling in T1D development. Female NOD mice lacking either
Ifnar1 or Ifngr1 showed some (but incomplete) protection, but males were protected only when both
IFN receptor genes were disrupted [22]. Notably, other studies reported no change in T1D development
in female NOD mice deficient in type I IFN signaling [37] or type II IFN signaling [38], but these
studies did not assess disease in males. In contrast to SS manifestations in NOD mice that occur only
in one sex (lacrimal disease in males, salivary gland disease in females), T1D may develop in both
males and females, though with different incidence generally favoring increased disease in females.
The female T1D bias related to differences in microbiota and was lost when NOD mice were kept in
germ free conditions [39,40]. MyD88-dependent signaling contributed to the role of microbiota on T1D
development in NOD mice. Both male and female MyD88-deficient NOD mice were protected from
diabetes but only when gut microbiota were present [41]. TLR7 signaling is MyD88-dependent, but our
findings here demonstrate a role for TLR7 signaling in T1D development only in males suggesting other
MyD88-dependent TLRs may compensate for the loss of TLR7 in females in our studies. TLR2-deficient
female NOD mice were partially protected from T1D development, and this also required the presence
of microbiota [42]. Both male and female TLR9-deficient NOD mice were protected from developing
T1D [43]. Together these data suggest that multiple TLRs play pathogenic roles in T1D development in
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NOD mice, but these roles differ between sexes with TLR7 providing a non-redundant role in T1D
development specifically in male NOD mice. Whether these sex differences in the role of TLR7 in T1D
development also depend on microbiota remains to be determined.
To better understand the role of TLR7 in lacrimal gland autoimmunity, we performed RNA
sequencing studies on lacrimal glands and identified both common and unique immune pathways
up-regulated in TLR7 or type I IFN-signaling-dependent manners. TLR7-dependent (but type I
IFN-independent) pathways suggested a role for TLR7 in driving B cell responses in the lacrimal
glands. Given the role of TLR7 in B cell biology, it is not surprising that three of the top five DE genes
in WT lacrimal glands were immunoglobulin-related genes. The remaining genes in the top 5 DE in
WT lacrimal glands in a TLR7-dependent manner (C4a and Il21) also play roles in B cell responses. C4a
encodes complement protein 4a, which plays a key role in both the classical and lectin pathways of the
complement cascade [44]. Deficiency in complement C4 protein has been associated with systemic
autoimmunity in humans including the recent finding that copy number variations in the C4A and C4B
genes were associated with increased risk of SS [45]. In humans, though, a decrease in copy number
resulting in lower protein levels was associated with higher risk of autoimmunity, which is contrary to
our findings of an increase in C4a expression associated with lacrimal gland inflammation in WT mice.
Since complement proteins are involved in the clearance of cell debris, the up-regulation of C4a may be
a consequence of the epithelial cell damage in the context of inflammation rather than a cause in NOD
mice, and the lack of C4 proteins due to decreased copy number variations in the associated genes
in humans may contribute to ongoing inflammation by failing to adequately clear the debris. Given
that NOD mice are deficient in C5, which is downstream of C4, they may have a similar deficiency
in clearing cell debris through complement-mediated mechanisms [46]. Despite the association of
deficiencies in C4 with autoimmunity, laser capture microdissection coupled with gene expression
studies demonstrated an increase in C4A expression in ductal cells isolated from minor salivary glands
of individuals with SS compared to healthy controls [47]. Together, these results suggest that C4 plays
a role in the immune regulation and/or dysregulation in the development of SS autoimmunity, but
additional studies are needed to further define these mechanisms.
Interleukin-21 (IL-21) is an inflammatory cytokine produced by innate and adaptive immune
cells that promotes B and T cell responses and may affect innate immune and non-immune cell
functions. The role of IL-21 in SS has been reviewed [48] and is further discussed in our recent report
demonstrating decreased lacrimal gland inflammation in Il21 KO NOD mice [26]. IL-21 may be
produced by follicular helper CD4 T cells (Tfh), which are characterized by expression of chemokine
receptor CXCR5 and transcription factor BCL6. In NOD lacrimal glands, another IL-21-producing CD4
population that lacks these classic Tfh markers has been identified [31]. This population of CD4 T cells
expressed high levels of PD1, ICOS, CD73, and CD200 by flow cytometry, and transcriptional analyses
demonstrated increased expression of Tbx1, Tnf, and Ifng suggesting a Th1-type profile. Among the
genes up-regulated in these IL-21-producing CD4 T cells was Sostdc1, which we have also identified here
as being highly DE in lacrimal glands of WT NOD mice in a TLR7-dependent manner. Sostdc1 encodes
Sclerostin domain-containing protein 1, a secreted protein that antagonizes both Wnt/β-catenin and
bone morphogenetic protein signaling. Sostdc1 plays many roles in development of tissues (including
development of the eye [49]) and in promoting cancer. Recent study using SOSTDC1-reporter mice
identified a potential regulatory role for Tfh-secreted SOSTDC1 in promoting the development of
regulatory follicular T cells in germinal centers following viral infection or immunization [50]. Notably,
these SOSTDC1-secreting Tfh cells expressed lower levels of Il21 and lost the ability to help B cells.
Whether the up-regulated Sostdc1 in WT NOD lacrimal glands plays a pathogenic or regulatory role
remains to be determined.
In summary, TLR7 is required for the spontaneous autoimmune manifestations that develop in
WT male NOD mice including lacrimal gland inflammation and T1D development but is dispensable
for the salivary gland inflammation and T1D that spontaneously develops in females. Moreover, TLR7
may provide a protective role in salivary gland disease in male NOD mice. In lacrimal glands, TLR7 is
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associated with many adaptive immune response genes common to a type I IFN response but also
promotes B cell activity within the lacrimal glands in a type I IFN-independent manner. Previous
microarray studies have identified increased Tlr7 expression (~3-fold) in lacrimal glands from WT
male compared to female NOD mice [51], which may be dependent on type I IFN signaling as Tlr7
was expressed ~4-fold greater in WT male NOD lacrimal glands compared to Ifnar1-deficient male
NOD lacrimal glands [26]. Thus, the pathogenic roles of TLR7 and type I IFN signaling in lacrimal
gland autoimmunity in NOD mice are complex (Figure 6). Additional functional studies are required
to determine the direct roles of TLR7 signaling in driving the gene expression changes reported here
or, instead, to determine if additional complex interactions downstream of TLR7 are required. One
key unanswered question that remains is what TLR7 ligands trigger the TLR7 response in lacrimal
glands in the context of SS-like autoimmunity. While the possibility of an exogenous viral trigger
for TLR7 signaling was not formally assessed, we favor the possibilities of either an endogenous
retrovirus or an endogenous nonviral ligand released from dying epithelial or immune cells during
lacrimal gland inflammation. In these regards, the recent identification of a new endogenous TLR7
ligand, U11snRNA [52], may warrant further study in NOD mice. Ultimately, identifying the innate
signals that drive lacrimal gland inflammation will provide targets for novel diagnostic tests and
therapeutic modalities.
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were bred in our colony [23]. Generation of NOD. Tlr7−/− (Tlr7 KO) mice were accomplished through 
targeting the Tlr7 gene by CRSPR/Cas9-mediated gene editing. NOD mouse embryos were 
microinjected with 3 pL of a solution containing Cas9 mRNA and single guide RNA (sgRNA) at 
respective concentrations of 100 ng/mL and 50 ng/mL. The sgRNA sequence was designed to target 
ATTTACAGGTGTTTTCGATG in Tlr7. Genomic tail DNA was screened by Sanger sequencing. The 
genomic region around the targeted site was amplified by PCR with primers Tlr7-geneF (5′-
ACTGACATATGCAAAGCATA-3′) and Tlr7-geneR (5′-ATTTCTTCCAGATGGTTCAGCCTA-3′). 
The resulting PCR product was purified and sequenced. During the screening of the N1 progeny, an 
allele with a 2 base-pair deletion was identified. The mouse was backcrossed to NOD for 1 generation, 
and the mutation was subsequently fixed to homozygosity. Male and female mice were used at ages 
ranging from 8–30 weeks. Mice were monitored for diabetes using Diastix urine glucose strips (Bayer 
Diagnostics, Whippany, NJ, USA). For diabetes studies, mice were monitored twice weekly and onset 
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Figure 6. Complex roles of TLR7 and type I IFN in the development of lacrimal gland inflammation.
TLR7 signaling drives a type I IFN response, and type I IFN signaling is associated with increased Tlr7
expression in male NOD mouse lacrimal glands. Each of these signals also drives different aspects
of the immune response including TLR7 driving a B cell response and type I IFN driving an innate
immune response. TLR7 and type I IFN signals together drive a more robust adaptive immune response
dominated by a T cell response. Together these signals lead to focal lymphocytic inflammation within
lacrimal glands that characterizes SS.
4. Materials and Methods
4.1. Mice
Male and female NOD/ShiLtJ (NOD) mice were purchased from The Jackson Laboratory (Bar Harbor,
ME) and bre in our colonies. The recently des ribed NOD. Ifnar1em16/em16 (Ifnar1 KO) mice were bred in
our colony [23]. Generation of NOD. Tlr7−/− (Tlr7 KO) mice were accomplished through targeting the
Tl 7 gene by CRSPR/Cas9-mediat d gene editing. NOD mouse embryos microinjecte with 3 pL
of a solution containing Cas9 m NA and single gui e RNA (sgRNA) at respective concentrations of
100 ng/mL and 50 ng/mL. The sgRNA sequence was designed to target ATTTACAGGTGTTTTCGATG
in Tlr7. Genomic ta l DNA was screene by Sanger sequencing. The genomic r gio around the
targeted site was amplified by PCR with pri ers T r7-geneF (5′-ACTGACATATGCAAAGCATA-3′)
a d Tlr7-geneR (5′-ATTTCTTCCAGATGGTTCAGCCTA-3′). The resulting PCR product was purified
and sequenced. During the screening of the N1 progeny, an allele with a 2 base-pair deletion was
id ntified. The mouse was b ckcross to NOD for 1 generation, and th mutation was subsequently
fixed to omozygosity. Male a d female m ce wer used at ages ranging from 8–30 weeks. Mice were
monitored for diabetes u ing Diastix urine gluc se strips (Bay r Diagnostics, Whippany, NJ, USA).
For diabetes studies, mice w re monitored twice weekly and onset of diabet s was defined by two
consecutive readings of >250 mg/dL. Mice were maintained in accordanc with Institutional Animal
Care and Use Committee Guidelines, and report d studies were approved by the Institution l Animal
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Care and Use Committees at the University of Iowa (0921655, approved 19 March 2019) and Medical
College of Wisconsin (AUA1863, approved 23 April 2019).
4.2. Flow Cytometry
Spleens were removed and splenocytes dissociated using the end of a 3 mL syringe plunger
through a 70 µm nylon mesh in Roswell Park Memorial Institute 1640 (RPMI) (Life Technologies,
Waltham, MA, USA) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, 100 µg/mL
streptomycin and 50 µM β-mercaptoethanol (complete RPMI). Red blood cells were depleted through
treatment with Ammonium-Chloride-Potassium (ACK) lysis buffer (Lonza, Mapleton, IL, USA). Single
cell splenocyte suspensions were stained with fluorophore-conjugated monoclonal antibodies: CD11c
(clone N418, eFluor450), B220 (clone RA3-6B2, PerCP-Cy5.5), TLR7 (clone A94B10, phycoerythrin
(PE)), mouse IgG1, kappa isotype (PE), purchased from eBioscience (San Diego, CA, USA), BioLegend
(San Diego, CA, USA), or BD Biosciences (San Jose, CA, USA). For intracellular staining for TLR7
(or isotype control), cells were fixed and permeabilized with the Foxp3/Transcription Factor Staining
Buffer Set per manufacturer’s protocol (eBioscience). Flow cytometry data acquisition was performed
on a BD LSR II (BD Biosciences) then analyzed with FlowJo software (Treestar Inc., Ashland, OR, USA).
For analyses, cells were gated based on size and complexity (FSC-A by SSC-A) then to identify singlets
(FSC-A by FSC-W). Singlets were subsequently gated on the CD11c+B220+ population to quantitate
TLR7 expression in this population of cells.
4.3. Histology and Quantitation of Exocrine Gland Inflammation
Quantitation of lacrimal and salivary gland inflammation was performed as previously described [53].
Briefly, exorbital lacrimal glands and submandibular salivary glands were fixed in formalin, processed,
embedded in paraffin, and 5 µm sections were stained with hematoxylin and eosin (H&E). Inflammation
was quantified in a blinded manner by standard light microscopy at 10× objective using standard
focus-scoring with a focus defined as an aggregate of at least 50 mononuclear cells and the focus score
defined as the number of foci per 4 mm2 of tissue. Tissue areas were calculated by ImageJ software [54]
using low magnification digital images obtained by scanning H&E-stained sections with the PathScan
Enabler IV (Meyer Instruments, Houston, TX, USA). The WT lacrimal and salivary glands in Figure 1
were previously published in comparison to another KO NOD strain [21] from the same colony as the
Tlr7 KO samples to which they were compared in this study. Representative H&E-stained sections in the
figure were obtained by whole-slide scans using the PathScan Enabler 5 (Meyer Instruments).
4.4. RNA Sequencing of Lacrimal Gland RNA and Bioinformatics Analyses
RNA was isolated from lacrimal glands per manufacturer’s protocol using RNeasy Plus Mini Kit
(Qiagen, Valencia, CA, USA) and submitted to the Iowa Institute of Human Genetics (IIHG) Genomics
Core Facility. Barcoded samples were pooled and sequenced using an Illumina HiSeq 4000. Reads
were demultiplexed and converted from the native Illumina BCL format to fastq format using an
in-house python wrapper to Illumina’s “bcl2fastq” conversion utility. FASTQ data were processed with
“bcbio”, a best-practices pipeline available at the open-source “bcbio-nextgen” project (https://github.
com/chapmanb/bcbio-nextgen; version 1.0.8) [55]. Reads were aligned to mm10 (genome FASTA
and annotations derived from ftp://ftp.ensembl.org/pub/release-97/fasta/mus_musculus/) reference
genomes using the ultra-rapid “hisat2” aligner (ver 2.1.0) [56]. Concurrently, reads were also quantified
against the transcriptome using the “salmon” aligner (ver 0.9.1) [55], yielding estimated counts and
values in length-normalized TPM (transcripts per million). Transcript-level abundances were converted
to gene-level counts using the “tximport” package from Bioconductor [56]. Read and alignment quality
control was performed with qualimap and samtools operating on the BAM alignments [57–59]. All
samples passed quality control with ~70% of reads mapping, and ~70% of mapped reads mapping
to exonic regions. Sequencing depth ranged from 48–70 M reads/sample. Inspection of the PCA
plot and lacrimal gland focus scores led to dropping one outlier sample from the Ifnar1 KO sample
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group (resulting in n = 3), which clustered with WT and had WT-level inflammation. No samples
were dropped from the Tlr7 KO (n = 5) or WT control (n = 3) groups. Gene-level counts were
used for differential gene expression analysis with DESeq2 [60]. Prior to calculating DE genes, the
counts table was filtered to exclude genes where at least two WT samples had a sum of counts
less than 30. This was done to prevent extreme outlier zero counts (i.e., dropouts) within the WT
replicates from creating very large fold-change artifacts. Data have been deposited in NCBI’s Gene
Expression Omnibus [61] and are accessible through GEO Series accession number GSE161184
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE161184). DE gene expression data was
analyzed using iPathwayGuide (Advaita Bioinformatics, https://www.advaitabio.com/ipathwayguide)
to detect and predict significantly impacted pathways, biological processes, and molecular interactions.
These analyses implement an “impact analysis” approach, which considers the direction and type of
all signals on a pathway along with the position, role and type of each gene [25,62–64]. For analyses of
enriched pathways and processes common to and unique to the two different RNA sequencing data
sets (TLR7-dependent and IFNAR1-dependent), genes up-regulated at least 2-fold in WT compared to
KO were analyzed with Metascape (http://metascape.org/gp/index.html#/main/step1) [65].
4.5. Quantitative PCR
Quantitative PCR (qPCR) was performed as previously described [23]. Briefly, lacrimal glands
were isolated and stored in RNAlater (Invitrogen, Carlsbad, CA, USA). Samples were homogenized
and total RNA isolated per manufacturer’s protocol using the RNeasy Plus Mini Kit (Qiagen). cDNA
was generated with the SuperScript II Reverse Transcriptase Kit (Invitrogen) and random primers
(Invitrogen). qPCR was performed using Power SYBR Green PCR Master Mix (Applied Biosystems,
Foster City, CA, USA) and appropriate gene-specific primers (Table 5) on a QS-7 FLEX Real Time PCR
System (Applied Biosystems). Number of gene transcripts were quantified based on standard curve
generated with plasmid cDNA and normalized to housekeeping gene Hk2.
Table 5. Primer sequences for qPCR analyses.
Target Sequence References
Tnfrsf13c Fwd AGATGGGCATGGTGGTACACA [66]
Tnfrsf13c Rev TGGAACTTGCTATGTAGACCAGGAT
Il21 Fwd GGACAGTGGCCCATAAATCA [62]
Il21 Rev CAGGGTTTGATGGCTTGAGT
Cxcr5 Fwd TGGCCTTCTACAGTAACAGCA [63]
Cxcr5 Rev GCATGAATACCGCCTTAAAGGAC




Cxcl13 Fwd CATAGATCGGATTCAAGTTACGCC [67]
Cxcl13 Rev TCTTGGTCCAGATCACAACTTCA
Hk2 Fwd CCCTGTGAAGATGTTGCCCAC [68]
Hk2 Rev TGCCCATGTACTCAAGGAAGT
4.6. Statistical Analyses
Statistical analyses were performed with Prism 8.4.3 (GraphPad, San Diego, CA, USA) except
for bioinformatics analyses using iPathwayGuide or Metascape as described above. Two-group
comparisons of data approximating normal distribution (flow cytometry data) were performed by
unpaired t-test with Welch’s correction for unequal variance where necessary. Two-group comparisons
of non-normally distributed data (focus scores, qPCR) were performed by Mann-Whitney test. Diabetes
incidence comparisons were performed by Log-rank test. p < 0.05 was considered significant.
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